Infinergy's 11.5-MW wind farm in UK could power GlaxoSmithKline's plant

(SeeNews) - Jan 25, 2013 - British wind power developer Infinergy said Thursday it was holding talks to sell electricity from its planned 11.5-MW wind farm in western England to GlaxoSmithKline (LON:GSK).

The British pharma major has expressed interest in buying power from the wind facility as its was searching for alternative ways of supplying electricity to its production site in Ulverston, north-western England, where it manufactures active pharmaceutical ingredients for antibiotics.

Infinergy's proposed Furness wind farm is a joint project with local cooperative Baywind. Infinergy has applied for the installation of three new machines and its partner will seek to replace five 2.5-MW turbines at its Harlock Hill wind park with new machines with higher capacity.

If the project is approved, GlaxoSmithKline could purchase the whole output of Infinergy's three wind turbines, equal to 6.9 MW, thus cutting its carbon dioxide emissions by 25%.

The pharmaceutical company has set a goal of lowering the carbon footprint of its Ulverston plant by 30% by end-2014, according to a company spokesman.

Join Renewables Now's free daily newsletter now!

More stories to explore
Share this story
About the author
Browse all articles from Veselina Petrova

Veselina Petrova is one of Renewables Now's most experienced green energy writers. For several years she has been keeping track of game-changing events both large and small projects and across the globe.

More articles by the author
5 / 5 free articles left this month
Get 5 more for free Sign up for Basic subscription
Get full access Sign up for Premium subscription